Results 71 to 80 of about 9,605 (202)

Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim The incidence of ulcerative colitis (UC) has been increasing in Asia. Comprehensive data on the long‐term course of moderate‐to‐severe UC remain scarce. This study investigated the clinical outcomes and factors associated with a disabling disease course in Korean patients with moderate‐to‐severe UC.
Byong Duk Ye, Hyo Jong Kim, Dong Il Park, Young Sook Park, Kang‐Moon Lee, Jong Pil Im, Sung‐Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee   +14 more
wiley   +1 more source

The role of neutrophils in the pathophysiology of inflammatory bowel diseases

Periodontology 2000, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens, Ekin Yay‐Kus, Rafael Scaf de Molon, Viorelia Stoica, Peter Rimmer, Josefine Hirschfeld, Asif Jilani Iqbal, Tariq Iqbal, Iain Chapple   +8 more
wiley   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 81-93, July 2026.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers

Head &Neck, Volume 48, Issue 7, Page 1876-1884, July 2026.
ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh, Labani Kole, Richard Sullivan, Shwetabh Sinha, Rathan Shetty, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Kumar Prabhash, Pankaj Chaturvedi   +9 more
wiley   +1 more source

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, Volume 159, Issue 1, Page 159-172, 1 July 2026.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Drug Design, Development and Therapy, 2017
Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M   +5 more
doaj  

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, Volume 101, Issue 7, Page 1359-1369, July 2026.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers [PDF]

Exploration of Musculoskeletal Diseases
Aim: To evaluate the impact of prescription, cost, and switching policy on the rate of switching from reference products to biosimilars. Methods: Analysis of an administrative database for prescription in a rheumatology division.
Fernando Perez-Ruiz, Elena Garmendia-Sanchez, Javier Arostegui-Lavilla, Javier Duruelo-Echevarrieta, Joana Atxotegi-Saenz de Buruaga, Mayra Nathali Rivas-Zavaleta, Javier Casas-Arrate, Maria del Consuelo Modesto-Caballero, Amaya de Basagoiti-Gorordo   +8 more
doaj   +1 more source

2024 Update of the Asia‐Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier ...
Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung, Yuko Kaneko, Wanruchada Katchamart, Manjari Lahiri, Chin Teck Ng, Babur Salim, Keshav Raj Sigdel, Shereen Ch'ng Suyin, Tsutomu Takeuchi, Galymzhan Togizbayev, Evan Vista, Sandini Wijeweera, Chuanhui Xu, Chak Sing Lau   +22 more
wiley   +1 more source